Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Are phase I studies without drug level determination acceptable?

P L Morselli1

  • 1Department of Clinical Research, Synthelabo Recherche, Paris, France.

Fundamental & Clinical Pharmacology
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CSF concentrations and serum protein binding of carbamazepine and carbamazepine-10,11-epoxide in epileptic patients.

British journal of clinical pharmacology·2012
Same author

GAMIAN-Europe/BEAM survey II: cross-national analysis of unemployment, family history, treatment satisfaction and impact of the bipolar disorder on life style.

Bipolar disorders·2004
Same author

Present and future role of Mental Illness Advocacy Associations in the management of the mentally ill: realities, needs and hopes at the edge of the third millennium.

Bipolar disorders·2001
Same author

Initiation of and adherence to treatment for mental disorders: examination of patient advocate group members in 11 countries.

Medical care·2000
Same author

Duration between onset and time of obtaining initial treatment among people with anxiety and mood disorders: an international survey of members of mental health patient advocate groups.

Psychological medicine·2000
Same author

Prevalence of nightmares and their relationship to psychopathology and daytime functioning in insomnia subjects.

Sleep·1997

Determining drug concentrations in phase I studies is crucial for understanding safety and effects. This analysis explores the necessity of drug level determination in early-phase clinical trials.

Area of Science:

  • Pharmacology
  • Clinical Trials
  • Drug Development

Background:

  • Phase I studies are critical for assessing new drug safety and efficacy.
  • Establishing dose-concentration-effect relationships informs clinical dosing and risk-benefit assessments.

Purpose of the Study:

  • To highlight the importance of drug level determination in phase I studies.
  • To discuss the necessity and implications of drug concentration monitoring in early-phase trials.

Main Methods:

  • Review of key objectives in phase I clinical trials.
  • Discussion of the role of pharmacodynamics and pharmacokinetics.

Main Results:

  • Drug level determination is essential for defining safety and pharmacodynamic profiles.

Related Experiment Videos

  • Understanding dose-concentration-effect correlations is vital for clinical application.

    • Conclusions:

    • Drug level determination is a necessary component of phase I studies.
    • The acceptability of phase I studies lacking drug level data requires careful consideration.